Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.

Sudewi Mukaromah KhoirunnisaFithria Dyah Ayu SuryanegaraDidik SetiawanMaarten Jacobus PostmaLisa Aniek de Jong

Published in: PloS one (2024)

In Indonesia, trastuzumab plus chemotherapy can be considered cost-effective compared to chemotherapy alone at a willingness-to-pay threshold of three times GDP, and it is likely most cost-effective in women <40 years of age.

Keyphrases

early breast cancer
epidermal growth factor receptor
locally advanced
metastatic breast cancer
polycystic ovary syndrome
squamous cell carcinoma
health insurance
radiation therapy
chemotherapy induced
type diabetes
skeletal muscle
data analysis